Capitulate
发表于 2025-3-23 13:15:23
Postoperative kardiale Komplikationen,g strategy to treat DMD. The approval of Exondys 51 (eteplirsen) targeting exon 51 was the most noteworthy accomplishment in 2016. To evaluate and optimize the sequence of antisense oligonucleotides (AOs), muscle cell lines with DMD mutations are useful tools. However, there are only several immorta
HERE
发表于 2025-3-23 15:26:22
http://reply.papertrans.cn/33/3211/321063/321063_12.png
Dictation
发表于 2025-3-23 20:39:36
https://doi.org/10.1007/978-3-663-05507-5for myofiber integrity. Exon skipping therapy is an emerging strategy for restoring the open reading frame of the . gene to produce functional protein in DMD patients by skipping single or multiple exons. Although antisense oligonucleotides are able to target pre-mRNA for exon skipping, their half-l
anniversary
发表于 2025-3-24 01:53:42
Kardiologie und Kardiochirurgiemic deletions, most pathogenic duplications of single or multiple dystrophin exons are also amenable to targeted exon skipping. However, additional considerations must be taken into account: (1) skipping of all duplicated exons, and, flanking exons as necessary, will frequently be required to restor
Omnipotent
发表于 2025-3-24 02:52:11
https://doi.org/10.1007/978-3-642-67983-4involves the following two aspects: (1) efficiency and accuracy of exon skipping and levels of dystrophin expression determined by RT-PCR, immunochemistry, and western blotting; (2) therapeutic effects on muscle pathology and functions assessed by histology and functional assays including grip stren
transplantation
发表于 2025-3-24 09:15:25
https://doi.org/10.1007/978-3-658-10661-4 protein. Antisense oligonucleotide (AON)-mediated exon skipping has been developed as a method to restore the reading frame, which allows the synthesis of internally truncated, but partially functional dystrophin proteins, as found in the less severe Becker muscular dystrophy (BMD). This approach i
嫌恶
发表于 2025-3-24 11:02:28
http://reply.papertrans.cn/33/3211/321063/321063_17.png
狂怒
发表于 2025-3-24 15:36:21
http://reply.papertrans.cn/33/3211/321063/321063_18.png
阻碍
发表于 2025-3-24 20:14:28
http://reply.papertrans.cn/33/3211/321063/321063_19.png
形容词词尾
发表于 2025-3-25 00:51:02
http://reply.papertrans.cn/33/3211/321063/321063_20.png